Platelet-derived growth factor C signaling is a potential therapeutic target for radiation proctopathy.

Lu, Weisi; Xie, Yunling; Huang, Binjie; Ma, Tenghui; Wang, Huaiming; Deng, Boxiong; Zou, Shaomin; Wang, Wencong et al. · Sci Transl Med · 2021

basic_science · Level V

Where this comes from

Abstract

Radiation proctopathy (RP) is characterized by inflammation of colorectal tissue and is a common complication of radiation therapy for pelvic malignancies with high incidence but lacking effective treatment. Here, we found that platelet-derived growth factor C (PDGF-C) and fibrosis markers were up-regulated in tissue samples from patients with RP and in rectal tissues after irradiation in a mouse model of RP. Genetic deletion of <i>Pdgf-c</i> in mice ameliorated RP-induced injuries. Genome-wide gene expression profiling and in vitro assays revealed that the promotive effect of PDGF-C in RP development was mediated by activation of PDGF receptors (PDGFRs) and C-X-C motif chemokine receptor 4, a proinflammatory chemokine regulated by transcription factor ETS variant transcription factor 1. Treatment with crenolanib, a selective inhibitor of PDGFRs, prevented or reduced RP in mice after irradiation. These results reveal that inhibition of PDGF-C signaling may have therapeutic value for the treatment of RP.

Medical subject headings